Atlas Venture Life Science Advisors’s Tectonic Therapeutic TECX Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio TECX Stock Details TECX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-78,447	Closed	-$3.62M	–	14
2024 Q4	$3.62M	Sell	78,447 -300,000	-79%	-$12.7M	0.44%	12
2024 Q3	$11.5M	Hold	378,447	–	–	1.06%	10
2024 Q2	$6.23M	Sell	378,447 -1	-0%	-$16	0.66%	12
2024 Q1	$5.81M	Hold	378,448	–	–	0.54%	13
2023 Q4	$6.18M	Hold	378,448	–	–	0.74%	13
2023 Q3	$6.99M	Hold	378,448	–	–	1.08%	12
2023 Q2	$4.31M	Hold	378,448	–	–	0.54%	13
2023 Q1	$4.54M	Buy	378,448 +1,709	+0.5%	+$23.8K	0.61%	13
2022 Q4	$3.22M	Hold	376,739	–	–	0.39%	14
2022 Q3	$2.9M	Hold	376,739	–	–	0.32%	15
2022 Q2	$4.16M	Hold	376,739	–	–	0.7%	13
2022 Q1	$5.97M	Hold	376,739	–	–	0.75%	14
2021 Q4	$17.4M	Buy	+376,739	New	+$21.6M	1.6%	10

Other funds holding TECX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Atlas Venture Life Science Advisors's TECX Position: Q1 2025 in Review

Atlas Venture Life Science Advisors sold out of Tectonic Therapeutic (TECX) in Q1 2025, closing a stake of 78,447 shares — an estimated $3.62M sold.

Atlas Venture Life Science Advisors first reported a position in TECX in Q4 2021 and held it in 13 quarters. The position peaked at $17.4M in Q4 2021. 78 funds tracked by Wall St. Rank hold TECX as of Q1 2025.

Atlas Venture Life Science Advisors reported no remaining Tectonic Therapeutic position as of Q1 2025 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 78,447 Tectonic Therapeutic shares in Q1 2025, an estimated $3.62M.
Atlas Venture Life Science Advisors first reported a position in Tectonic Therapeutic in Q4 2021 and held it in 13 quarters.
Atlas Venture Life Science Advisors's Tectonic Therapeutic position peaked at $17.4M in Q4 2021.
78 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2025.

Based on Atlas Venture Life Science Advisors's 13F filing for Q1 2025, filed 14 May 2025.